Miscellaneous ocular agents:

Indications for: CIMERLI

Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).

Adult Dosage:

Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.

Children Dosage:

Not established.

CIMERLI Contraindications:

Ocular or periocular infections.

CIMERLI Warnings/Precautions:

Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy. Nursing mothers.

CIMERLI Classification:

Vascular endothelial growth factor (VEGF) inhibitor.

Adverse Reactions:

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR); possible embryo-fetal toxicity.

Generic Drug Availability:


How Supplied:

Single-dose vial (2mL)—1